Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Hereditary Sensory and Autonomic Neuropathies 3Endometrial Neoplasms 3Neoplasms 2Breast Neoplasms 2Advanced Solid Tumor 2Triple Negative Breast Neoplasms 1Neoplasm Metastasis 1Lung Neoplasms 1Head and Neck Neoplasms 1Genital Diseases 1Colonic Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Endometrioid 1Advanced Nonhematologic Malignancies 1

Interventions

Specimen Handling 3Nivolumab 3olaparib 2durvalumab 2Paclitaxel 2Magnetic Resonance Spectroscopy 2Ipilimumab 2Carboplatin 2CTLA-4 Antigen 2temsirolimus 1sintilimab 1serabelisib 1sapanisertib 1rucaparib 1pembrolizumab 1palbociclib 1defactinib 1copanlisib 1ceralasertib 1cediranib 1capivasertib 1cabozantinib 1adavosertib 1Taxes 1Radiation 1RO5126766 1Platinum 1Megestrol Acetate 1Medroxyprogesterone Acetate 1Immunoglobulin G 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Carcinoma, Endometrioid × serabelisib × Clear all
NCT06463028 2025-12-24

Sapanisertib and Serabelisib (PIKTOR) With Paclitaxel and a Substudy With an Insulin-Suppressing Diet in Patients With Advanced/Recurrent Endometrial Cancer

Faeth Therapeutics

Phase 2 Recruiting
40 enrolled
Gynecologic

Genital Diseases, Hereditary Sensory and Autonomic Neuropathies, Endometrial Neoplasms, Carcinoma, Endometrioid

Data powered by HemOnc (CC BY 4.0) Colophon âš¡